



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A23K 1/00	A1	(11) International Publication Number: WO 95/12987 (43) International Publication Date: 18 May 1995 (18.05.95)
(21) International Application Number: PCT/US94/09137 (22) International Filing Date: 22 August 1994 (22.08.94) (30) Priority Data: 149,305 9 November 1993 (09.11.93) US (71) Applicant: CHURCH & DWIGHT COMPANY, INC. [US/US]; 469 North Harrison Street, Princeton, NJ 08543 (US). (72) Inventors: VINCI, Alfredo; 13 Marc Drive, Dayton, NJ 08810 (US). LAJOIE, M., Stephen; 14 Launcelot Lane, Basking Ridge, NJ 07926 (US). CUMMINGS, Kenneth, R.; 165 Opossum Road, Skillman, NJ 08558 (US). FORREST, Ronald, L.; 522 Windsor Commons, Cranbury, NJ 08512 (US). (74) Agents: DEPAOLI, George, A.; Suite 1103, 2231 Crystal Drive, Arlington, VA 22202 (US) et al.		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). Published <i>With international search report.</i>
(54) Title: RUMINANT FEED SUPPLEMENT PRODUCT		
(57) Abstract In one embodiment this invention provides a process for preparing a fatty acid calcium salt ruminant feed supplement product which contains an incorporated methionine hydroxy analog calcium salt additive. The dietary product can function as a rumen bypass feed supplement, and permit a beneficial increase in the nutrient fat content of the feed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

RUMINANT FEED SUPPLEMENT PRODUCT**CROSS-REFERENCE TO RELATED APPLICATIONS**

The present patent application is a continuation-in-part of patent application
5 S.N. 08/007,013, filed January 21, 1993, which is a continuation of patent application S.N. 07/802,261, filed December 4, 1991; incorporated by reference.

BACKGROUND OF THE INVENTION

Conventional cattle feeds such as corn and
10 alfalfa often fail to provide sufficient energy for cattle, especially lactating dairy cattle during periods of heavy milk production. Feed containing a high proportion of corn also has a tendency to depress the milk fat content of the milk produced by
15 such cattle. Fat is an excellent energy source, and it is known that if the proportion of fat in cattle food is increased, lactating dairy cattle produce high milk yields without draining their reserves of body fat and without diminishing the proportion of
20 milk fat in the milk produced.

However, it has been found that if the proportion of fat in the diet of cattle exceeds about 2% of the total feed in solids, the feed has toxic effects upon the microorganisms in the rumen
25 of the cattle. It appears that fat reduces the

growth rate or even kills certain microorganisms which digest fiber in the cow's rumen, thereby lowering fiber digestibility. This deleterious effect on the cow's rumen is particularly true of
5 unsaturated fats. Although the decreased fiber digestion in the rumen is partially compensated by greater fiber digestion in the lower parts of the alimentary canal, such later fiber digestion produces a blend of different fatty acids than that
10 which is produced by the digestion in the rumen, and the different blend of fatty acids is less suited to the cow's metabolism.

It is known also that triglycerides and free fatty acids can physically coat fibrous or
15 cellulosic material in the rumen and inhibit fermentation of the material by the bacteria. This has an adverse effect on the total digestibility of the diet, and can result in a reduced yield of milk and butter-fat.

20 There has been a continuing need for new dietary supplements for animal feedstuff which can be fed to ruminant animals without interfering with feed metabolism by rumen microorganisms.

United States Patent Numbers 4,642,317;
25 4,826,694; 4,853,233; and 4,909,138 describe the incorporation of insoluble fatty acid salts in ruminant feed as a means of increasing the fat content of the feed without deleteriously affecting

the ruminant digestion cycle. A feed additive such as fatty acid calcium salt functions as a rumen bypass product, and is subsequently metabolized in the abomasum or small intestine of the ruminant.

- 5 This type of feed optionally can include a biologically active ingredient such as an aminoacid.

Accordingly, it is an object of the invention to provide a process for the production of a ruminant feed supplement product which can
10 function as a rumen bypass composition, and permit a beneficial increase in the dietary fat content of the feed.

It is another object of this invention to provide a fatty acid salt ruminant feed supplement
15 product which has incorporated one or more additional biologically active nutrient ingredients having rumen bypass protection.

Other objects and advantages of the present invention shall become apparent from the
20 accompanying description and examples.

DESCRIPTION OF THE INVENTION

One or more objects of the present invention are accomplished by the provision of a process for the preparation of a ruminant feed supplement product which comprises (1) forming an admixture of ingredients comprising (a) at least one C_{14} - C_{22} fatty acid, (b) calcium oxide in about a 0.8-1.5 equivalent basic weight quantity per equivalent weight of C_{14} - C_{22} fatty acid, (c) between about 0.0-0.4 equivalent weight of basic alkali metal compound per equivalent weight of C_{14} - C_{22} fatty acid, (d) between about 10-80 weight percent of an aqueous medium, based on the weight of fatty acid, and (e) a biologically active ingredient comprising methionine hydroxy analog alkaline earth metal salt; and (2) recovering the salt product after completion of the exothermic salt-forming reaction.

The C_{14} - C_{22} fatty acid component of the salt-forming reaction medium consists of one or more saturated or unsaturated carboxylic acids such as those derived from beef and mutton tallow, lard, cottonseed oil, palm oil, and the like.

Palm fatty acid distillate is a commercial product produced by distilling the fatty acids present in natural palm oil. A distillate product typically has the following weight percent content:

5

Free fatty acids	60-90
Water	<1
Triglycerides	10-40
Unsaponifiabiles	<3

- 5 The fatty acids in the free fatty acids and the triglycerides consist of the following weight percent:

	Palmitic acid	38-50
	Oleic acid	35-40
10	Linoleic acid	5-10
	Stearic acid	3-6
	Lauric acid	1-3

- 15 Beef tallow acids are available commercially as a byproduct obtained by alkaline extraction of waste beef fat and subsequent acidification, and normally contain the following weight percent of fatty constituents:

	Free fatty acids	60-90
	Triglycerides	10-40
20	Water	<1
	Unsaponifiabiles	<3

The fatty acids in the free fatty acids and in the triglycerides have the following weight percent content:

6

Palmitic acid	22-28
Oleic acid	38-44
Linoleic acid	3-6
Stearic acid	18-24

5 Because C_{14} - C_{22} fatty acids and glycerides
are susceptible to atmospheric oxidation, it is
advantageous to incorporate an oil-soluble
antioxidant, and a chelating agent to bind any
ferric, copper, zinc or other metal capable of
10 catalyzing atmospheric oxidation. Suitable
quantities for inclusion in the fatty acid bulk are
about 0.03-0.1% or higher of antioxidant as
permitted by regulation, and about 0.05-0.3% of
chelating agent, based on the weight of fatty acid.

15 Illustrative of preferred additives are
butylated hydroxytoluene antioxidant and citric acid
chelating agent. The chelating agent is added in an
edible solvent such as propylene glycol to
facilitate blending into the fatty acid.

20 The calcium oxide component of the process
can be utilized either alone or in combination with
magnesium oxide. The calcium oxide component can be
calcined limestone, which contains 93-96% CaO and
not more than about 7% of $CaCO_3$. The basic oxide
25 preferably has a particle size which passes a
100 mesh U.S. standard screen.

A basic alkali metal compound such as sodium carbonate can be included as an optional ingredient, to moderate the conversion of the free fatty acid ingredient to the corresponding calcium salt.

The biologically active ingredient quantity employed in the process typically will vary in the range between about 0.05-20 weight percent, based on the weight of C₁₄-C₂₂ fatty acid ingredient.

The biologically active ingredient comprises methionine hydroxy analog alkaline earth metal salt, such as the calcium salt or magnesium salt or a mixture thereof. The biologically active ingredient content additionally can contain an additive selected from nicotinamide, lysine, and salts thereof.

As illustrated in Example I, the selection of biologically active ingredient is restricted because many important nutrient compounds such as aminoacids do not survive the calcium oxide hydration and fatty acid salt-formation exothermic reaction conditions which are inherent in the invention process embodiments. Nutrient compounds such as nicotinic acid, methionine and choline are chemically transformed under the exothermic reaction conditions characteristic of the invention process.

As illustrated in Example II, if methionine hydroxy analog calcium salt is employed as a nutrient additive in a fatty acid calcium salt-

forming reaction medium, then the salt-forming reaction proceeds smoothly to completion. The final product is in the form of free-flowing friable granules, and it consists essentially of a fatty acid calcium salt matrix having the methionine hydroxy analog calcium salt additive homogeneously distributed and incorporated therein. The encapsulated additive has rumen bypass protection.

Example II also demonstrates that the use of methionine hydroxy analog per se, or the sodium salt thereof, yields a fatty acid calcium salt product which is less pure, and is not in a free-flowing friable granule form.

In another embodiment this invention provides a ruminant feed supplement product comprising (1) at least one C_{14} - C_{22} fatty acid calcium salt ingredient; and (2) between about 0.05-20 weight percent of a biologically active additive ingredient comprising methionine hydroxy analog alkaline earth metal salt, based on the weight of fatty acid calcium salt ingredient; wherein the biologically active additive is homogeneously distributed and incorporated in the fatty acid calcium salt ingredient, and has rumen bypass protection.

The ruminant feed supplement product can be produced by the present invention process, and can be obtained as a high purity composition in friable granule form.

The invention process can be conducted in a batch reactor or as a continuous operation. The fatty acid, calcium oxide, biologically active ingredient and aqueous medium can be admixed
5 simultaneously, or the fatty acid and calcium oxide can be blended first and then combined with the other processing components.

In one processing method the fatty acid is heated to 80°-110°C or higher, and then mixed with
10 the basic oxide. After the aqueous medium and biologically active ingredient are added to the mixture, there is a short induction period which is followed by exothermic calcium oxide hydrating and fatty acid salt-forming reactions.

15 The amount of aqueous medium employed is sufficient to support the calcium oxide hydrating and fatty acid salt-forming reactions, and preferably is vaporized as steam during the exothermic reaction period to yield a friable fatty
20 acid salt product which in granule form is suitable for use as an animal feed supplement.

A present invention fatty acid salt product is adapted to function as a rumen bypass dietary supplement in ruminant feed. An important
25 advantage of a present invention dietary supplement composition is the rumen bypass protection which extends to all the biologically active ingredients of the composition, which normally are metabolized in the rumen.

10

The following Examples are further illustrative of the present invention. The components and specific ingredients are presented as being typical, and various modifications can be
5 derived in view of the foregoing disclosure within the scope of the invention.

EXAMPLE I

This Example illustrates the chemical stability of a variety of biologically active ingredients under calcium oxide hydration and fatty acid salt-formation exothermic reaction conditions in accordance with the present invention process.

The fatty acid component is a palm fatty acid distillate of the following composition:

	Lauric acid	2.3%
10	Palmitic acid	49.9%
	Stearic acid	5.4%
	Oleic acid	35.0%
	Linoleic acid	7.4%

Calcium oxide (100 g) and palm fatty acid distillate (700 g) are admixed, and then the mixture is blended with an aqueous medium (300 g) with stirring. Steam evolves during the exothermic calcium oxide hydration and fatty acid salt-forming reactions, and the final product is in the form of a friable solid.

The aqueous medium in separate runs contains 35 grams respectively of nicotinic acid, nicotinamide, choline, methionine, methionine hydroxy analog or methionine hydroxy analog calcium salt following the procedure of the control run.

12

Under the reaction conditions the quantity of nicotinic acid, methionine or choline ingredient in the initial stage of the process is diminished in the final product, while the original content of
5 nicotinamide, methionine hydroxy analog or methionine hydroxy analog calcium salt is intact in the final product.

13

EXAMPLE II

This Example illustrates the effect of a nutrient additive on a fatty acid calcium salt-forming reaction.

5

A.

A calcium salt-forming reaction is conducted with the following ingredients:

	palm fatty acid distillate	167.60 g
	calcium oxide	24.72 g
10	methionine hydroxy analog	7.60 g
	water	30.60 g

The palm fatty acid distillate oil is heated to 95°C. The methionine hydroxy analog is admixed with the heated oil, followed by the
15 addition of calcium oxide and water with stirring.

Over a reaction period of 30 minutes, the palm fatty acid distillate remains substantially unreacted. The presence of methionine hydroxy analog has an inhibiting effect on the fatty acid
20 calcium salt-forming reaction.

14

B.

	palm fatty acid distillate	167.60 g
	calcium oxide	24.72 g
	methionine hydroxy analog	7.60 g
5	water	30.60 g
	surfactant ⁽¹⁾	1.00 g

The palm fatty acid distillate oil is heated to 95°C. The surfactant is added to the heated oil with stirring, followed by the addition
10 of methionine hydroxy analog with 1000 rpm stirring. The lime and water are added, and the reaction medium at 95°C is stirred for a one hour period.

The palm fatty acid distillate remains substantially unreacted in the salt-forming reaction
15 medium.

⁽¹⁾ Myvatex Texture Lite; monoglycerides;
Eastman Chemical Company

15

C.

palm fatty acid distillate	167.60 g
calcium oxide	24.72 g
methionine hydroxy analog	7.60 g
5 water	30.60 g

The methionine hydroxy analog is blended with the water. The palm fatty acid distillate oil is heated to 95°C, and the lime and water are added to the oil with stirring. The reaction medium is
10 heated to 107°C, and a partial conversion of fatty acid to fatty acid calcium salt occurs.

The final product consists of a tacky mass of agglomerated solids.

16

D.

palm fatty acid distillate	167.60 g
calcium oxide	24.72 g
methionine hydroxy analog calcium salt	9.00 g
5 water	30.60 g

The reaction medium is prepared following the procedure of section A above.

The salt-forming reaction proceeds over a period of about two hours. The final product is recovered and dried. The product consists essentially of palm fatty acid calcium salt with a content of homogeneously distributed and incorporated methionine hydroxy analog calcium salt. The product is in the form of friable granules.

15 If methionine hydroxy analog sodium salt is employed in place of the corresponding calcium salt, the salt-forming reaction period is prolonged, and the final product is in the form of tacky solids.

EXAMPLE III

This Example illustrates the continuous production of a dietary fatty acid calcium salt product in accordance with the present invention.

5 The process is operated continuously with equipment which is essentially the same as described and illustrated with reference to Fig. 1 of U.S. 4,826,694 by W. McAskie.

10 Calcium oxide from a hopper and hot palm oil distillate (96°C) for a supply line are mixed in predetermined proportions in a mixing pump. An aqueous medium and crystalline methionine hydroxy analog calcium salt are added to the reactant blend by separate supply lines.

15 The aqueous medium is supplied to the reaction zone at a rate which provides about 30 weight percent of water; and 3 weight percent of methionine hydroxy analog calcium salt is supplied, based on the weight of palm fatty acid distillate.

20 The hydrated mixture formed in the process is passed through a mixing pump and the resultant semi-liquid reaction medium at about 100°C is discharged as a spread layer onto a continuously moving conveyor belt. Steam evolves from the
25 conveyor transported reaction mass.

 At the end of the conveyor belt solid lumps of reaction product fall through a sizing machine onto a second conveyor belt. In this

conveying zone the salt-forming reaction and evolution of water proceed to completion. The essentially dry fatty acid calcium salt product is passed through a sifter, and collected in bags
5 suitable for transportation and storage.

The residence time on the first conveyor is about 30 minutes, and the overall production time from reactant mixing to collection of the dry granulated product is about 2.5 hours.

10 The final product has a total fatty acid calcium salt content of 85 weight percent, a methionine hydroxy analog calcium salt content of 2.6 weight percent, a water content of about 3-5 weight percent, and an ash content of about
15 15 weight percent.

The invention fatty acid calcium salt product can be incorporated as a dietary supplement in cattle feed such as hay silage or corn silage, in a calculated quantity which will provide each animal
20 about 800-1000 grams per day of fatty acid salt, and about 25-30 grams per day of methionine hydroxy analog calcium salt.

The process is repeated, except that 1.5 weight percent each of nicotinamide and lysine
25 hydrochloride as additional biologically active ingredients, based on the weight of fatty acid, are premixed with the methionine hydroxy analog calcium salt prior to admixture with the other process ingredients.

WHAT IS CLAIMED IS:

1. A process for the preparation of a ruminant feed supplement product which comprises (1) forming an admixture of ingredients comprising
5 (a) at least one C_{14} - C_{22} fatty acid, (b) calcium oxide in about a 0.8-1.5 equivalent basic weight quantity per equivalent weight of C_{14} - C_{22} fatty acid, (c) between about 0.0-0.4 equivalent weight of basic alkali metal compound per equivalent weight of C_{14} - C_{22}
10 fatty acid, (d) between about 10-80 weight percent of an aqueous medium, based on the weight of fatty acid, and (e) a biologically active ingredient comprising methionine hydroxy analog alkaline earth metal salt; and (2) recovering the salt product
15 after completion of the exothermic salt-forming reaction.
2. A process in accordance with claim 1 wherein the fatty acid and calcium oxide compounds are premixed before admixture with the other process
20 ingredients.
3. A process in accordance with claim 1 wherein the C_{14} - C_{22} fatty acid ingredient is a mixture comprising 0-10 percent lauric acid, 0-60 percent palmitic acid, 0-10 percent stearic acid,
25 0-60 percent oleic acid, and 0-10 percent linoleic acid.

4. A process in accordance with claim 1 wherein the biologically active ingredient content is between about 0.05-20 weight percent, based on the weight of C₁₄-C₂₂ fatty acid.

5 5. A process in accordance with claim 1 wherein the biologically active ingredient content additionally contains an additive selected from nicotinamide, lysine, and salts thereof.

10 6. A process in accordance with claim 1 wherein the biologically active ingredient is methionine hydroxy analog calcium salt or magnesium salt or a mixture thereof.

15 7. A process in accordance with claim 1 wherein the exothermic salt-forming reaction medium is at a temperature between about 60°-110°C.

8. A process in accordance with claim 1 wherein water evaporation occurs during the salt-forming reaction, and the salt product is recovered in the form of friable granules.

20 9. A ruminant feed supplement product comprising (1) at least one C₁₄-C₂₂ fatty acid calcium salt ingredient; and (2) between about 0.05-20 weight percent of a biologically active additive ingredient comprising methionine hydroxy

21

analog alkaline earth metal salt, based on the weight of fatty acid calcium salt ingredient; wherein the biologically active additive is homogeneously distributed and incorporated in the fatty acid calcium salt ingredient, and has rumen bypass protection.

10. A ruminant feed supplement product in accordance with claim 9 wherein the biologically active ingredient content additionally contains an additive selected from nicotinamide, lysine, and salts thereof.

11. A ruminant feed supplement product in accordance with claim 9 wherein the methionine hydroxy analog additive is a calcium salt or magnesium salt or a mixture thereof.

12. A ruminant feed supplement product in accordance with claim 9 wherein the fatty acid calcium salt ingredient consists of palm fatty acid distillate calcium salt.

13. A ruminant feed supplement in accordance with claim 9 which is in friable granule form, and is the product of a claim 1 process.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/09137

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A23K 1/00

US CL :426/72, 74, 648, 656

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 426/72, 74, 648, 656, 658, 807

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,729,896 (SAWHILL) 08 MARCH 1988. SEE COLUMN 3, LINES 58-61.	1-13
Y	US, A, 4,826,694 (McAskie) 02 MAY 1989. SEE THE ABSTRACT.	1-13
Y	US, A, 5,236,723 (LAJOIE ET AL.) 17 AUGUST 1993. SEE THE ABSTRACT AND COLUMN 6, LINES 54-59.	1-13

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be part of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*& document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 OCTOBER 1994

Date of mailing of the international search report

DEC 02 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JOSEPH M. GOLIAN

Facsimile No. (703) 305-3230

Telephone No. (703) 308-3851

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/15488

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4388327	A	14-06-1983	AT 12339 T	15-04-1985
			AU 547123 B	10-10-1985
			AU 8986582 A	05-05-1983
			BR 8206189 A	20-09-1983
			CA 1175281 A	02-10-1984
			DK 481782 A	01-05-1983
			EG 15770 A	30-09-1986
			EP 0079164 A	18-05-1983
			GR 77723 A	25-09-1984
			JP 58081741 A	17-05-1983
			ZA 8207896 A	27-06-1984
<hr/>				
DE 19524054	A	18-01-1996	AU 690714 B	30-04-1998
			AU 2888395 A	09-02-1996
			AU 2981595 A	09-02-1996
			BR 9508383 A	23-12-1997
			CA 2194437 A	25-01-1996
			CN 1152912 A	25-06-1997
			CN 1152911 A	25-06-1997
			WO 9601809 A	25-01-1996
			WO 9601808 A	25-01-1996
			EP 0770061 A	02-05-1997
			EP 0770060 A	02-05-1997
			JP 10502378 T	03-03-1998
			JP 10502382 T	03-03-1998
			PL 318105 A	12-05-1997